d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Progress in Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/bs.pbr.2018.07.008PMID 30471683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

  2018cited by this paper
• The Effects of Hallucinogens on Gene Expression.

  2018cited by this paper
• Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression

  2018cited by this paper
• Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life‐threatening disease: A systematic review

  2018cited by this paper
• Psychedelics: Where we are now, why we got here, what we must do.

  2018cited by this paper
• Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study

  2018cited by this paper
• Psychedelic Drugs in Biomedicine.

  2017cited by this paper
• Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

  2017cited by this paper
• The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.

  2017cited by this paper
• Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

  2017cited by this paper
• Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

  2017cited by this paper
• Crystal Structure of an LSD-Bound Human Serotonin Receptor.

  2017cited by this paper
• Potential Therapeutic Effects of Psilocybin

  2017cited by this paper
• Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies

  2017cited by this paper
• In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1

  2016cited by this paper
• Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

  2016cited by this paper
• Erratum to: Psychosis associated with acute recreational drug toxicity: a European case series

  2016cited by this paper
• Neural correlates of the LSD experience revealed by multimodal neuroimaging

  2016cited by this paper
• Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years

  2016cited by this paper
• d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology

  2016cited by this paper
• The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.

  2016cited by this paper
• Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

  2016cited by this paper
• Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study

  2016cited by this paper
• Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine

  2016cited by this paper
• The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors.

  2016cited by this paper
• The paradoxical psychological effects of lysergic acid diethylamide (LSD)

  2016cited by this paper
• Psychedelics in the treatment of unipolar mood disorders: a systematic review

  2016cited by this paper
• LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality

  2016cited by this paper
• Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

  2016cited by this paper
• Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

  2016cited by this paper
• LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

  2015cited by this paper
• Psychedelics not linked to mental health problems or suicidal behavior: A population study

  2015cited by this paper
• Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

  2015cited by this paper
• The hallucinogenic world of tryptamines: an updated review

  2015cited by this paper
• Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).

  2015cited by this paper
• Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.

  2015cited by this paper
• Multimodal Imaging of Dynamic Functional Connectivity

  2015cited by this paper
• Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.

  2015cited by this paper
• Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

  2015cited by this paper
• Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.

  2015cited by this paper
• Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

  2014cited by this paper
• The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice

  2014cited by this paper
• The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

  2014cited by this paper
• Ketamine – More mechanisms of action than just NMDA blockade

  2014cited by this paper
• Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia.

  2014cited by this paper
• Anxiety and depression in psychosis: a systematic review of associations with positive psychotic symptoms

  2013cited by this paper
• Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.

  2013cited by this paper
• Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice.

  2013cited by this paper
• Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations

  2013cited by this paper
• Effects of Schedule I drug laws on neuroscience research and treatment innovation

  2013cited by this paper
• Psychedelics and Mental Health: A Population Study

  2013cited by this paper
• Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis.

  2013cited by this paper
• A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight

  2013cited by this paper
• Shaping the renaissance of psychedelic research.

  2012cited by this paper
• Default mode network activity and connectivity in psychopathology.

  2012cited by this paper
• Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.

  2012cited by this paper
• Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

  2011cited by this paper
• Antidepressant medications reduce subcortical–cortical resting-state functional connectivity in healthy volunteers

  2011cited by this paper
• Anxiety dissociates dorsal and ventral medial prefrontal cortex functional connectivity with the amygdala at rest.

  2011cited by this paper
• TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity

  2011cited by this paper
• Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

  2011cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010cited by this paper
• The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

  2010cited by this paper
• Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light

  2010cited by this paper
• Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI

  2009cited by this paper
• Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.

  2009cited by this paper
• The Pharmacology of Lysergic Acid Diethylamide: A Review

  2008cited by this paper
• AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes.

  2008cited by this paper
• Serotonin research: contributions to understanding psychoses.

  2008cited by this paper
• Prevalence and correlates of depression, anxiety, and suicidality among university students.

  2007cited by this paper
• Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

  2007cited by this paper
• The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval

  2007cited by this paper
• Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members.

  2007cited by this paper
• A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis

  2007cited by this paper
• National institute for Health and Clinical excellence guidance

  2007cited by this paper
• Serotonergic vulnerability and depression: assumptions, experimental evidence and implications

  2007cited by this paper
• Hallucinogen-Induced UP States in the Brain Slice of Rat Prefrontal Cortex: Role of Glutamate Spillover and NR2B-NMDA Receptors

  2006cited by this paper
• Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant

  2006cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• A renaissance in trace amines inspired by a novel GPCR family.

  2005cited by this paper
• Mapping cortical activity elicited with electrical microstimulation using FMRI in the macaque.

  2005cited by this paper
• Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis

  2005cited by this paper
• Quality-of-life impairment in depressive and anxiety disorders.

  2005cited by this paper
• The 5-HT1A receptor and the stimulus effects of LSD in the rat

  2005cited by this paper
• Efficacy of antidepressants in adults

  2005cited by this paper
• Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics

  2005cited by this paper
• Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase‐1, C/EBP‐β and ILAD‐1, a novel gene with homology to arrestins

  2004cited by this paper
• Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.

  2004cited by this paper
• Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli

  2004cited by this paper
• Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats

  2004cited by this paper
• Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.

  2003cited by this paper
• Hallucinogen persisting perception disorder: what do we know after 50 years?

  2003cited by this paper
• Is there a role for 5-HT1A agonists in the treatment of depression?

  2003cited by this paper
• The validity of the Hospital Anxiety and Depression Scale. An updated literature review.

  2002cited by this paper
• Mescaline use for 5700 years.

  2002cited by this paper
• A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain

  2002cited by this paper
• Trace amines: Identification of a family of mammalian G protein-coupled receptors

  2001cited by this paper
• Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons.

  2001cited by this paper
• Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.

  2001cited by this paper
• DMT: The Spirit Molecule: A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences

  2000cited by this paper

• Psychedelics in Focus: Clinical Trial Advancements, USFDA Breakthrough Designations, Innovative Approaches, Legal and Regulatory Aspects

  2026cites this paper
• Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder

  2025cites this paper
• Possible Involvement of Hallucinogenic Effects in the Aversive Effects Induced by Kappa‐Opioid and 5‐HT2A /2C Receptor Agonists in Mice

  2025cites this paper
• Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.

  2025cites this paper
• Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review

  2025cites this paper
• Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review

  2025cites this paper
• Psychedelics and the future evolution of humanity

  2025cites this paper
• Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings

  2025cites this paper
• History of psychedelic drug science and molecular pharmacology.

  2025cites this paper
• Risks of using psilocybin in treatment of treatment-resistant depression

  2025influential citation
• Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View

  2025cites this paper
• Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish

  2024cites this paper
• Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration

  2024cites this paper
• Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms

  2024cites this paper
• Ayahuasca for the treatment of alcohol use disorder.

  2024cites this paper
• Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine—A Systematic Review and Meta-Analysis

  2024cites this paper
• Psychedelics and schizophrenia: a double-edged sword

  2024cites this paper
• Antidepressant Effect and Mechanism of Picea mariana Essential Oil on Reserpine-Induced Depression Model Mice

  2024cites this paper
• Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor

  2024cites this paper
• The role of serotonin in depression—A historical roundup and future directions

  2024cites this paper
• Perioperative considerations for patients exposed to hallucinogens

  2024cites this paper
• Unblinding and demand characteristics in the treatment of depression.

  2023cites this paper
• Molecular and Medical Aspects of Psychedelics

  2023cites this paper
• Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders

  2023cites this paper
• Psychedelics for treatment resistant depression: are they game changers?

  2023cites this paper
• Evidencias y perspectivas del potencial antidepresivo del “alcaloide mágico” psilocibina: una revisión narrativa

  2023cites this paper
• Psychedelics and neonihilism: connectedness in a meaningless world

  2023cites this paper
• 5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system

  2023cites this paper
• Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms

  2023cites this paper
• The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.

  2023cites this paper
• Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives

  2023cites this paper
• Spatial correspondence of LSD-induced variations of brain functioning at rest with serotonin receptor expression.

  2023cites this paper
• Role of Psychedelics in Treatment-Resistant Depression.

  2023cites this paper
• Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.

  2023cites this paper
• Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment

  2022cites this paper
• Reconstituting the complete biosynthesis of D-lysergic acid in yeast

  2022cites this paper
• Hallucinogenic drugs and their potential for treating fear‐related disorders: Through the lens of fear extinction

  2022cites this paper
• Lysergic Acid Diethylamide Produces Anxiogenic Effects in the Rat Light/Dark Text and Elevated Plus Maze

  2022cites this paper
• Individual differences in the positive outcome from adolescent ketamine treatment in a female mouse model of anorexia nervosa involve drebrin A at excitatory synapses of the medial prefrontal cortex

  2022cites this paper
• 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs

  2022cites this paper
• Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity

  2022cites this paper
• The Missing Piece? A Case for Microglia’s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics

  2022cites this paper
• A unified model of ketamine’s dissociative and psychedelic properties

  2022cites this paper
• Lysergic Acid Diethylamide Produces Anxiogenic Effects in the Rat Light / Dark Text and Elevated Plus Maze

  2022cites this paper
• Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission

  2021cites this paper
• Potencial terapéutico de los alucinógenos en las cefaleas: una revisión teórica

  2021cites this paper
• Psychedelics, Sociality, and Human Evolution

  2021cites this paper
• Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults

  2021cites this paper
• Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.

  2021cites this paper
• Potencial terapéutico de los alucinógenos en las cefaleas: una revisión teórica

  2021cites this paper
• Psychedelic medicines for mood disorders: current evidence and clinical considerations

  2021cites this paper
• Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

  2021cites this paper
• Psychedelic-Assisted Therapy.

  2021cites this paper
• Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.

  2021cites this paper
• Psychedelic Chemicals and Depression Treatment

  2021influential citation
• From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

  2021cites this paper
• Therapeutic Use of Hallucinogens

  2021cites this paper
• The neurochemistry of hypnotic suggestion

  2021cites this paper
• Psilocybin-Assisted Therapy: A Double-Blind Randomized Controlled Trial

  2021cites this paper
• Psychedelic Medicines in Major Depression: Progress and Future Challenges.

  2021cites this paper
• Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice

  2021influential citation
• An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression

  2021cites this paper
• Use and abuse of dissociative and psychedelic drugs in adolescence

  2021cites this paper
• Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models

  2020cites this paper
• Apotential role for psilocybin in the treatment of obsessive-compulsive disorder

  2020cites this paper
• Psilocybin-assisted therapy and depression - a systematic review

  2020cites this paper
• Psychedelic‐assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports

  2020cites this paper
• Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

  2020cites this paper
• Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

  2020cites this paper
• P.668 Lysergic acid diethylamide (LSD) modulates social behavior and neuronal activity of pyramidal neurons in the medial prefrontal cortex

  2020cites this paper
• A potential role for psilocybin in the treatment of obsessive-compulsive disorder

  2020cites this paper
• Depression: Biological markers and treatment

  2020cites this paper
• Constitutive activity of 5-HT receptors: Factual analysis.

  2020cites this paper
• Effect of the 5-HT2C Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study

  2019cites this paper
• Ketamine Within Clinically Effective Range Inhibits Glutamate Transmission From Astrocytes to Neurons and Disrupts Synchronization of Astrocytic SICs

  2019cites this paper
• Medicines to Enhance Self-Consciousness, Mindfulness and Healthy Ageing?

  2019cites this paper
• New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

  2019cites this paper
• Epidermal absorption in male scrotum of topical application of psychedelic drugs: times and effects

  2019cites this paper
• Adenylyl cyclase 7 and neuropsychiatric disorders: A new target for depression?

  2019cites this paper
• Lysergic Acid Diethylamide (LSD)

  2019cites this paper
• Hallucinogen use is associated with mental health and addictive problems and impulsivity in university students

  2019cites this paper
• Human Self-Domestication and the Extended Evolutionary Synthesis of Addiction: How Humans Evolved a Unique Vulnerability.

  2019cites this paper
• The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.

  2019cites this paper
• Rapid-acting antidepressants.

  2019cites this paper
• Opportunities in Novel Psychotropic Drug Design from Natural Compounds

  2019cites this paper
• An introduction to psychedelic neuroscience.

  2018influential citation
• Rapid-Acting Antidepressants.

  2018cites this paper
• THE PSYCHEDELIC ALTERED STATE OF CONSCIOUSNESS

  year unknowninfluential citation